Toxicology
January 5, 2005
Helena Carmo, Jan G Hengstler, Douwe De Boer et al.
85 citations
The psychoactive designer drug 2C-B is broken down by liver cells from humans, monkeys, dogs, rabbits, rats, and mice through oxidative deamination and demethylation, producing several metabolites. A previously unknown metabolite, 4-bromo-2,5-dimethoxy-phenol (BDMP), appeared only in mouse cells, while another metabolite, 2-(4-bromo-2-hydroxy-5-methoxyphenyl)-ethanol (B-2-HMPE), formed in human, monkey, and rabbit cells but not in dog, rat, or mouse cells. Toxic effects on liver cells varied little across species but showed large differences among cells from three human donors, indicating that individual human variation may be more important than species differences in determining 2C-B toxicity.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences
November 25, 2004
Helena Carmo, Douwe De Boer, Fernando Remião et al.
32 citations
The psychoactive drug 2C-B, sold as 'Ecstasy', is metabolized in mice, producing several metabolites detectable in urine by GC/MS. Unchanged 2C-B and these metabolites were identified, providing data that may help understand the drug's biological and toxicological effects and aid forensic analysis of samples from human abusers.
Science Letters
April 17, 2026
Francisco Sacadura, Cláudia Marques, Andreia Machado Brito-Da-Costa et al.
Both pure psilocybin and a Psilocybe cubensis extract altered the gut microbiota of male Wistar Han rats over two weeks. Fecal samples analyzed by 16S rRNA amplicon sequencing showed that microbial community structure shifted away from baseline and control profiles at day 7 and diverged further by day 14. The effect was more pronounced in rats given pure psilocybin than in those given the whole mushroom extract, suggesting the extract's additional compounds may modulate the impact. The results indicate a time-dependent modulation of gut microbiota by both treatments, with differential magnitude between the pure compound and the whole extract.
Science Letters
April 17, 2026
Diana Dias Da Silva, Andreia Machado Brito-Da-Costa, Francisco Sacadura et al.
Pure psilocybin and whole Psilocybe cubensis extract produce distinct behavioral and toxicological effects in male Wistar Han rats. Pure psilocybin decreased conditioned place preference scores at days 1 and 7, indicating aversive or non-reinforcing effects, and reduced exploratory activity. The extract did not significantly alter preference but transiently increased exploratory behavior at day 7. Peripherally, pure psilocybin increased relative liver weight, suggesting hepatic stress, while the extract reduced renal lipid peroxidation, indicating a protective or antioxidant effect likely from other compounds. These differences highlight the importance of matrix effects in psychedelic research.
Pharmaceuticals (Basel, Switzerland)
February 25, 2021
Carolina Lobato-Freitas, Andreia Machado Brito-Da-Costa, Ricardo Jorge Dinis-Oliveira et al.
ADB-FUBINACA and AMB-FUBINACA are synthetic cannabinoids up to 140 and 85 times more potent than THC, the main psychoactive compound in cannabis. First synthesized in 2009, ADB-FUBINACA appeared recreationally in Japan in 2013, with fatal cases by 2015; AMB-FUBINACA emerged in 2014 and has caused multiple intoxication and death outbreaks. When smoked, effects begin within 10 to 15 seconds and last up to 60 minutes. Both act as full agonists at the CB1 receptor, producing cardiovascular and neurological effects such as altered perception, agitation, anxiety, paranoia, hallucinations, loss of consciousness, chest pain, hypertension, tachycardia, and seizures. The review calls for more research on their toxicokinetics to improve detection and treatment.
Molecular Neurobiology
June 1, 2009
João Paulo Capela, Helena Carmo, Fernando Remião et al.
MDMA (ecstasy) is a widely abused hallucinogenic drug that can damage nerve cells in both animals and humans. In rats and some mouse strains, it destroys serotonin-producing nerve endings and causes broader brain damage in areas like the cortex, hippocampus, and striatum. In human users, reduced serotonin markers correlate with lasting memory and learning problems. The neurotoxicity involves multiple factors: hyperthermia, metabolism by monoamine oxidase, dopamine oxidation, serotonin transporter activity, nitric oxide and peroxynitrite formation, glutamate excitotoxicity, serotonin 2A receptor activation, and toxic metabolites. This review summarizes the history, pharmacology, metabolism, and cellular/molecular mechanisms of MDMA neurotoxicity to aid development of treatments for long-term psychiatric complications.